EQS-News: MEDICLIN AG: Annual General Meeting approves all proposed resolutions
|
EQS-News: MEDICLIN AG
/ Key word(s): AGM/EGM
Offenburg, 4 June 2025
MEDICLIN AG: Annual General Meeting approves all proposed resolutions Offenburg, 4 June 2024: MEDICLIN Aktiengesellschaft (MEDICLIN) held its Annual General Meeting as a virtual Annual General Meeting on Wednesday, 4 June.
The Executive Board was extremely positive about the 2024 financial year, with the post-acute segment in particular, which reflects the company's rehabilitation expertise, making considerable progress. This momentum is to be continued in the current year. Successful despite changes in the healthcare market Dr Joachim Ramming, CEO, praised the financial results for 2024 as a milestone in the company's history. "We have not only achieved the highest sales, but also the strongest EBIT in our history," emphasised the CEO in his review. At the same time, he referred to the far-reaching changes in the healthcare market: increasing outpatient care, digital care models and an intensified shortage of specialists. These trends call for agile action and targeted investments. "Thanks to our forward-looking projects MEDICLIN HOME, MEDICLIN DIRECT and MEDICLIN CAMPUS, we are utilising change as an opportunity and are well positioned for the future," he commented. Information on the Annual General Meeting All resolutions proposed by the management were approved by a majority. 91.42% of the share capital was represented at the Annual General Meeting. The resolution on the appropriation of net retained profits and the distribution of a dividend was approved by a majority of 99.67%. In addition to the discharge of the Executive Board and Supervisory Board with majorities of 99.20% and 99.20% respectively, the re-election of two Supervisory Board members was also on the agenda. The previous Chairman of the Supervisory Board, Dr Jan Liersch, and Mr Marco Walker, who was already a member of the Supervisory Board, were re-elected to the Board. KPMG AG Wirtschaftsprüfungsgesellschaft was appointed as auditor and group auditor for the 2025 financial year with a majority of 99.20%. The Annual General Meeting confirmed the remuneration of the Supervisory Board with a majority of 99.99%. All voting results can be viewed under the following link. MEDICLIN will publish its interim report for the first half of 2025 on 31 July. For further information: MEDICLIN Aktiengesellschaft Okenstrasse 27 77652 Offenburg Investor Relations Ender Gülcan Phone: 0781/488-326 ender.guelcan@mediclin.de Public Relations Dr Janina Lossen Phone: 0781/488-180 janina.lossen@mediclin.de www.mediclin.de About MEDICLIN Aktiengesellschaft (Ticker: MED; WKN: 659 510) MEDICLIN includes 31 clinics, six care facilities and ten medical care centers. The group has around 8,200 beds/care places and employs around 9,900 people. In a strong network, MEDICLIN offers the patients integrative care from the first visit to the doctor through the operation and subsequent rehabilitation to outpatient aftercare. Doctors, therapists and nurses work together in a carefully coordinated manner. MEDICLIN designs the care and support of people in need of care according to their individual needs and personal needs. MEDICLIN ─ a company of the Asklepios Group
04.06.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | MEDICLIN AG |
| Okenstraße 27 | |
| 77652 Offenburg | |
| Germany | |
| Phone: | +49 (0)781 488-326 |
| Fax: | +49 (0)781 488-184 |
| E-mail: | ender.guelcan@mediclin.de |
| Internet: | www.mediclin.de |
| ISIN: | DE0006595101 |
| WKN: | 659510 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2150686 |
| End of News | EQS News Service |
|
|
2150686 04.06.2025 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | ||
| Sales1 | 673,09 | 659,86 | 673,14 | 704,70 | 730,07 | 748,75 | 778,00 | |
| EBITDA1,2 | 93,58 | 77,50 | 85,22 | 90,92 | 98,73 | 103,77 | 115,00 | |
| EBITDA-Margin3 | 13,90 | 11,75 | 12,66 | 12,90 | 13,52 | 13,86 | 14,78 | |
| EBIT1,4 | 22,41 | 0,15 | 11,56 | 19,52 | 12,72 | 53,49 | 63,00 | |
| EBIT-Margin5 | 3,33 | 0,02 | 1,72 | 2,77 | 1,74 | 7,14 | 8,10 | |
| Net Profit (Loss)1 | 9,68 | -0,04 | 1,49 | 9,72 | -10,72 | 24,91 | 35,00 | |
| Net-Margin6 | 1,44 | -0,01 | 0,22 | 1,38 | -1,47 | 3,33 | 4,50 | |
| Cashflow1,7 | 69,59 | 118,69 | 81,97 | 34,64 | 78,00 | 50,57 | 74,00 | |
| Earnings per share8 | 0,20 | -0,19 | 0,03 | 0,20 | -0,23 | 0,52 | 0,74 | |
| Dividend per share8 | 0,05 | 0,00 | 0,00 | 0,00 | 0,00 | 0,04 | 0,04 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: KPMG
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Mediclin | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| 659510 | DE0006595101 | AG | 179,55 Mio € | 06.12.2000 | Kaufen | 8FW9FWGV+63 |
| PE 2026e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 5,82 | 17,70 | 0,33 | 17,10 | 0,73 | 2,23 | 0,24 |
|
Dividend '2023 in € |
Dividend '2024 in € |
Dividend '2025e in € |
Div.-Yield '2025e in % |
| 0,00 | 0,04 | 0,04 | 1,06% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 28.06.2026 | 04.05.2026 | 30.07.2026 | 04.11.2025 | 27.03.2026 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| +12,80% | +22,77% | +56,20% | +52,42% | -65,64% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.